PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Co-careldopa - Parkinson's disease (challenge test)
PAD Profile : Co-careldopa - Parkinson's disease (challenge test)
Keywords :
PD, challenge test, levodopa, dopamine, carbidopa
Brand Names Include :
Sinemet, Sinemet CR, Sinemet Plus, Caramet, Half-Sinemet CR, Lecado, Duodopa, Apodespan
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
NICE issued a Do Not Do Recommendation in June 2006 (updated July 2017) which states:
"Acute levodopa and apomorphine challenge tests should not be used in the differential diagnosis of parkinsonian syndromes."
Associated BNF Codes
04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism